论文部分内容阅读
目的比较苯那普利+氢氯噻嗪与海捷亚治疗原发性高血压的效果及安全性。方法 100例患者随机分成2组,苯那普利+氢氯噻嗪组(50例,苯那普利10 mg+氢氯噻嗪12.5 mg,每日1次);海捷亚组(50例,海捷亚每日1片),疗程8周,在治疗的第1、2、4、8周末记录血压、心率及不良反应情况。结果治疗8周后两组血压均下降,笨那普利+氢氯噻嗪组显效23例(46.0%),有效13例(26.0%),无效14例(28.0%),总有效率72.0%;海捷亚组显效21例(42.0%),有效13例(26.0%),无效16例(32.0%),总有效率68.0%。两组对比差异无统计学意义(P>0.05)。结论两组药物对原发性高血压的疗效无显著性差异。
Objective To compare the efficacy and safety of benazepril with hydrochlorothiazide and Hytera in the treatment of essential hypertension. Methods 100 patients were randomly divided into 2 groups: benazepril + hydrochlorothiazide group (50 cases, benazepril 10 mg + hydrochlorothiazide 12.5 mg once daily) ) For 8 weeks. Blood pressure, heart rate and adverse reactions were recorded on the 1st, 2nd, 4th and 8th week of treatment. Results After 8 weeks of treatment, the blood pressure decreased in both groups, with 23 cases (46.0%) in cinapril + hydrochlorothiazide group, 13 (26.0%) effective and 14 (28.0%) ineffective with a total effective rate of 72.0% Subgroup was effective in 21 cases (42.0%), effective in 13 cases (26.0%), ineffective in 16 cases (32.0%), the total effective rate was 68.0%. There was no significant difference between the two groups (P> 0.05). Conclusion There is no significant difference between the two groups in the efficacy of drugs on essential hypertension.